Newsbenzinga
Penny Stock VolitionRx Expands Addressable Markets With Key Diagnostic Validations
· Published
Article summary
VolitionRx reports 112% revenue growth in H1 2026 while advancing its Nu.Q diagnostic platforms across sepsis and oncology markets.
An excerpt from the original article.
Comments —
Loading comments…